Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.

Education

Pharmaceutical

Eli Lilly

David Hyman is the Chief Medical Officer of [Loxo Oncology](/org/loxo-oncology) at Eli Lilly. David was previously an Associate Professor of Medicine at Weill Cornell Medicine from January 2015 to December 2019, and an Associate Member at Memorial Sloan Kettering Cancer Center from January 2009 to January 2020. Prior to that, they were a Medicine Resident at New York Presbyterian Hospital from July 2006 to July 2009.

David Hyman is an MD who graduated from Joan & Sanford I. Weill Medical College of Cornell University. David also has a BS in Biology from [Brown University](/org/brown-university). David is certified by the [American Board of Internal Medicine](/org/american-board-of-internal-medicine) in Medical Oncology and Internal Medicine.

David Hyman reports to Daniel M. Skovronsky, SVP & Chief Scientific Officer.

David Hyman

In this role, Beiser oversees all aspects of the company's corporate communications strategy, including internal and external corporate communications, media relations, crisis management, executive communications, digital and social media, and corporate brand and reputation management.

Beiser has a strong background in healthcare communications, most recently serving as senior vice president and chief communications officer for [Kaiser Permanente](/org/kaiser-permanente). Before joining [Kaiser Permanente](/org/kaiser-permanente), Beiser held the role of senior advisor with [APCO Worldwide](/org/apco-worldwide) and also served as global chair, corporate practice, for Edelman Public Relations Worldwide. Earlier, she served as executive vice president, corporate communications, for [Hilton Worldwide](/org/hilton-worldwide), and was vice president of corporate communications for Discover Financial Services. Beiser has also worked for several of the world's most well-known public relations firms, including Burson-Marsteller, Golin and Hill & Knowlton where she focused on healthcare and other clients in highly regulated industry sectors.

Beiser is a member and a former trustee of the Arthur W. Page Society, the professional organization of chief communication officers, as well as a former trustee of the Institute for Public Relations. She currently serves on the boards of Bright Pink, a nonprofit organization that helps to save lives from breast and ovarian cancer by empowering women to know their risk and manage their health proactively, and Break the Cycle, a nonprofit organization aimed at ending domestic violence and promoting healthy relationships among teenagers. Beiser holds a bachelor's degree in political science from Northwestern University and a master's degree from the Medill School of Journalism at Northwestern.

Kathryn Beiser

Alonzo Weems is executive vice president, enterprise risk management and chief ethics and compliance officer of Eli Lilly and Company. He leads Lilly’s global ethics and compliance function. 

Since joining Lilly as an attorney in 1997, Alonzo has held a variety of roles providing strategic legal counsel across different areas of the business ranging from oncology clinical development and global health outcomes to commercialization of products in multiple therapeutic areas. His prior leadership roles include vice president and deputy general counsel for corporate legal functions, general counsel for Lilly USA and general counsel for biomedicines and diabetes. In his role as general counsel for the global biomedicines and diabetes businesses, Alonzo led the legal teams in Australia, Canada, Europe, Japan and China, Lilly’s largest markets outside of the United States. Prior to becoming general counsel for Lilly USA, he served as general counsel and corporate secretary for Lilly Canada. From 2006-2008, Alonzo oversaw the refresh of the company’s workforce diversity and inclusion strategy in his role as director for global workforce diversity.

He earned a Bachelor of Arts degree from [Wabash College](/org/wabash-college) and a Doctor of Jurisprudence from the Indiana University Maurer School of Law.  

He currently serves on the Board of Visitors for the IU Maurer School of Law and the boards of directors for the International School of Indiana and [Early Learning Indiana](/org/early-learning-indiana). Alonzo is a member of the Chief Ethics and Compliance Officer Steering Committee for the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). He is a past president and member of the Indiana Board of Law Examiners and a past member of the law section executive committee for Pharmaceutical Research and Manufacturers of America (PhRMA). 

Alonzo Weems

Diogo Rau is executive vice president & chief information and digital officer of Eli Lilly and Company. He leads Lilly’s information technology, cybersecurity, digital health, and advanced analytics and data science functions.

Diogo joined Lilly in May 2021. Prior to joining Lilly, he led information technology for retail and online stores at Apple, Inc. During his 10 years at Apple, he led the development and implementation of the technology supporting the Apple Online Store and Apple retail stores, including the e-commerce platform, mobile point of sale, the Apple Store App and systems used by store team members.

Prior to joining Apple, Diogo was a partner with [McKinsey & Company](/org/mckinsey-company), where he led the North America IT organization and governance practice. Diogo began his career as a consultant at A.T. Kearney and later founded GiftGateway, a software company that brought rewards and recognition online.

Diogo graduated from [Stanford University](/org/stanford) with a bachelor's degree in computer science and a master's degree in industrial engineering and engineering management.

Diogo Rau

Ilya Yuffa is executive vice president of Eli Lilly and Company and president of Lilly International.

With a tenure of more than 24 years at Lilly, Ilya most recently served as vice president of U.S. Diabetes for Lilly USA from 2018 to 2020. 

Since joining Lilly in 1996 as a financial analyst, Ilya has held a number of positions in finance, business development, sales and general management. He served as managing director of the Israeli affiliate from 2008 until 2011, senior sales director of osteoporosis from 2011 until 2013, and held senior leadership positions within six sigma and ethics and compliance from 2013 until 2017. In 2017, Ilya was named president and general manager of Lilly’s Italy Hub, leading the commercialization of the entire Lilly portfolio in more than 25 countries.

Born in St. Petersburg, Russia, Ilya grew up in Colorado. His career has taken him around the world, and he has lived and worked in the United Kingdom, Czech Republic, Italy and Israel. Ilya earned a bachelor of science degree from Tulane University in 1996, and a master of business administration degree from the London Business School in 2002.

He is a former board member of PhRMA industry association in Israel and Farmindustria in Italy, and he led as vice chair of the Italian American Pharmaceutical Group. Ilya currently serves on the Downtown Rebuilding & Recovery Committee for Downtown Indy, Inc.

Ilya Yuffa

Gabrielle Sulzberger serves as a strategic advisor to Two Sigma Impact, a New York based private equity fund. She was elected to the Eli Lilly and Company board of directors in 2021.

Previously, Sulzberger was a general partner of Rustic Canyon/Fontis Partners, a private equity fund based in Pasadena, California, focused on socially responsible investing. Sulzberger has previously served as principal of several private equity funds over her 30-year career in financial services, as well as chief financial officer of several public and private companies.

Sulzberger holds a bachelor of arts degree from the Woodrow Wilson School of [Princeton University](/org/princeton), a master of business administration from [Harvard Business School](/org/harvard-business-school), and a juris doctor from Harvard Law School.

Sulzberger is a member of the boards of directors of [Mastercard](/org/mastercard), [Brixmor Property Group](/org/brixmor-property-group), [Cerevel Therapeutics](/org/cerevel-therapeutics) and several other private companies. Among her previous board positions, Sulzberger served as chairman of the board of Whole Foods.

Sulzberger is also trustee of the [Ford Foundation](/org/ford-foundation) and is chair of its governance committee. She also serves on the boards of [The Metropolitan Museum of Art](/org/the-metropolitan-museum-of-art), Sesame Street Workshop, Time’s Up and Trinity Church Wall Street. She is a Henry Crown Fellow of the Aspen Institute. 

Gabrielle Sulzberger

Mike Mason is senior vice president of Eli Lilly and Company and president of Lilly Diabetes. He is responsible for the global development and commercialization of Lilly’s diabetes franchise.

Mike joined Lilly in 1989. During his 30-year career with the company, he has held various roles in research and development (R&D), engineering, manufacturing, supply chain, strategy, business development, market research and corporate leadership. His extensive experience covers a variety of therapeutic areas such as neuroscience, osteoporosis, oncology, urology and endocrinology.

Mike currently serves on the board of directors for United Schools of Indianapolis. He is a previous chair of St. Vincent Indianapolis Hospital’s board of directors, and also previously served on the board of directors of Canada’s Research-Based Pharmaceutical Companies.

Michael B. Mason

Sandy Richards

Raghuram P

Marschall S. Runge, M.D., Ph.D., is executive vice president for Medical Affairs at the University of Michigan, Dean of the Medical School and CEO of Michigan Medicine. Prior to joining the University of Michigan in March 2015, he was executive dean and chair of the Department of Medicine at the UNC School of Medicine, where he was instrumental in guiding the academic and clinical leadership of the School of Medicine and the UNC Health Care System. He was also principal investigator and director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC Chapel Hill. He was elected to the Eli Lilly and Company board of directors in 2013.

Before joining the UNC faculty in 2000, Dr. Runge held the John Sealy Distinguished Chair in Internal Medicine and was director of the Division of Cardiology and the Sealy Center for Molecular Cardiology at the University of Texas Medical Branch at Galveston.

Dr. Runge earned his doctorate in molecular biology at [Vanderbilt University](/org/vanderbilt-university) and his medical degree from Johns Hopkins School of Medicine, where he also completed a residency in internal medicine. He was a cardiology fellow and faculty member at Harvard Medical School’s Massachusetts General Hospital before joining [Emory University](/org/emory-university) as an associate professor of medicine in 1989. Dr. Runge has been a physician-scientist for his entire career, combining basic and translational research and education with the care of patients with cardiovascular diseases. He is the author of over 200 publications in the field and holds five patents for novel approaches to health care.

Marschall S. Runge

Katherine Baicker, Ph.D., is the Dean of the Harris School of Public Policy at the University of Chicago. She is also a research associate at the National Bureau of Economic Research. She was elected to the Eli Lilly and Company board of directors in 2011.

Baicker received a bachelor of arts degree in economics, magna cum laude, from [Yale University](/org/yale-university) in 1993, and a Ph.D. in economics from [Harvard University](/org/harvard) in 1998.

Before serving at the University of Chicago, she was the C. Boyden Gray professor of health economics at the Harvard T.H. Chan School of Public Health, where she now holds an appointment as an adjunct professor. From 1998 to 2005, Baicker was assistant professor and associate professor of economics at [Dartmouth College](/org/dartmouth).

From 2005 to 2007, she served as a Senate-confirmed member of the Council of Economic Advisers in the Executive Office of the President, where she played a leading role in the development of health policy. Baicker serves on the Panel of Health Advisers to the Congressional Budget Office and on the editorial boards of Health Affairs and the Journal of Health Economics. She is an elected member of the National Academy of Medicine. She has served as a commissioner on the Medicare Payment Advisory Commission, chair of the Group Insurance Commission of Massachusetts, chair of the board of directors of Academy Health, and chair of the Social Sciences and Population Studies study section of the [National Institutes of Health](/org/national-institutes-of-health).

Katherine Baicker

Ralph Alvarez joined Advent International Corporation, a large private global equity firm, in July 2017 as an operating partner. He was elected to the Eli Lilly and Company board of directors in 2009.

Born in Cuba, he received his bachelor’s degree in business administration from the [University of Miami](/org/university-of-miami).

Alvarez retired as president and chief operating officer of McDonald’s Corporation in 2009. Prior to joining McDonald’s in 1994, he held leadership positions at Burger King Corporation and Wendy’s International, Inc. He held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald’s USA. Before joining the U.S. business, Alvarez was president of McDonald’s Mexico. From July 2004 until January 2005, he was president of McDonald’s USA, where he led a team that aligned employees, owner/operators and suppliers behind the company’s “Plan to Win” strategy – the catalyst for the turnaround of its U.S. business. Alvarez served as president of McDonald’s North America from January 2005 until August 2006. In this role, he was responsible for all McDonald’s restaurants in the U.S. and Canada. Alvarez became president and chief operating officer in August 2006. He set the global strategy and directed operations for 32,000 McDonald’s restaurants in 118 countries.

Alvarez is an active advocate for education. He serves on the President’s Council and the School of Business Administration Board of Overseers for the [University of Miami](/org/university-of-miami). Alvarez is also a member of the boards of directors of Lowe’s Companies, Inc. and Dunkin’ Brands Group, Inc. He also previously served on the boards of McDonald’s Corporation, Realogy Holdings Corp., [KeyCorp](/org/keycorp), and Skylark Co., Ltd.

Ralph Alvarez

J. Erik Fyrwald joined [Syngenta](/org/syngenta) in June 2016 as president and chief executive officer. He was elected to the Eli Lilly and Company board of directors in 2005.

Fyrwald served as chief executive officer of [Univar](/org/univar) from May 2012 until May 2016. In 2008, following a 27-year career at [DuPont](/org/dupont), he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with [Ecolab](/org/ecolab) Inc. Following the merger, Fyrwald served as president of [Ecolab](/org/ecolab).

From 2003 to 2008, Fyrwald served as group vice president of the agriculture and nutrition division at E.I. du Pont de Nemours and Company. From 2000 until 2003, he was vice president and general manager of [DuPont](/org/dupont)’s nutrition and health business.

Fyrwald attended the [University of Delaware](/org/university-of-delaware), where he received a bachelor of science degree in chemical engineering in 1981. He also completed the advanced management program at [Harvard Business School](/org/harvard-business-school).

Fyrwald serves on the boards of directors of [Syngenta](/org/syngenta), Bunge Limited, CropLife International, the Swiss-American Chamber of Commerce and the UN World Food Program Farm to Market Initiative.

J. Erik Fyrwald

Juan R. Luciano is chairman of the board of directors and chief executive officer of Archer Daniels Midland Company (ADM). He was elected to the Eli Lilly and Company board of directors in 2016. He was elected lead independent director, effective May 2019.

Luciano joined ADM in 2011 as executive vice president and chief operating officer. He was named president in February 2014. He became chief executive officer in January 2015 and chairman of the board in January 2016.

Under Luciano’s leadership, ADM has taken significant actions to deliver shareholder value through strategic growth, including investments in port facilities in Europe and South America, feed plants in the U.S. and China, and expanded sweetener production capacity in Eastern Europe. Luciano has also led ADM’s continued expansion into the ingredients business.

At the same time, Luciano has spearheaded operational excellence initiatives that have significantly enhanced the company’s capital, cost and cash positions, and has led efforts to continue building the organization’s internal leadership capacity.

Before joining ADM, Luciano had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the Performance division.

Luciano holds an industrial engineering degree from the Buenos Aires Institute of Technology. He is a trustee of the Boys and Girls Clubs of America and serves as an alternate director on the board of directors for Wilmar International Limited.

Juan R. Luciano

William G. Kaelin, Jr., M.D. is professor in the Department of Medicine at the [Dana-Farber Cancer Institute](/org/dana-farber-cancer-institute-inc) and at the Brigham and Women’s Hospital, Harvard Medical School. He was elected to the Eli Lilly and Company board of directors in 2012.

Kaelin received his degree in medicine from [Duke University](/org/duke-university) in 1982 and was a house officer and chief resident in internal medicine at Johns Hopkins Hospital. He was a medical oncology clinical fellow at the [Dana-Farber Cancer Institute](/org/dana-farber-cancer-institute-inc) and a postdoctoral fellow in the laboratory of Dr. David Livingston, where he began his studies of tumor suppressor proteins. He became an independent investigator at Dana-Farber in 1992 and Professor of Medicine at Harvard Medical School in 2002. He joined the [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute) in 1998.

Kaelin is a member of the American Society of Clinical Investigation (ASCI) and the American College of Physicians. He recently served on the National Cancer Institute Board of Scientific Advisors, the American Association for Cancer Research (AACR) Board of Trustees and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center, the Richard and Hinda Rosenthal Prize from the AACR and a Doris Duke Distinguished Clinical Scientist award. In 2007, he was elected to the National Academy of Medicine. In 2010, Kaelin was elected to the [National Academy of Sciences](/org/national-academy-of-sciences) and was a co-recipient of a 2010 Canada Gairdner International Award. In 2012, Kaelin was a co-recipient of both the [ASCI](/org/asci)’s Stanley J. Korsmeyer Award and the Scientific Grand Prix of the Foundation Lefoulon-Delalande and was elected to the Association of American Physicians. In 2014, he won the Wiley Prize in Biomedical Sciences from the [Rockefeller University](/org/rockefeller-university) and the Steven C. Beering Award from the Indiana University School of Medicine. In 2016, he won the Albert Lasker Basic Medical Research Award.

William G. Kaelin Jr.

Karen Walker is senior vice president and chief marketing officer, [Cisco](/org/cisco) Systems. She was elected to the Eli Lilly and Company board of directors in 2018.

Based in San Jose, Walker is responsible for the company's marketing and communications group. Her 20-plus years in the IT industry have included senior field and marketing leadership roles in Europe, North America and the Asia-Pacific region. Prior to joining [Cisco](/org/cisco), she held multiple business and consumer leadership positions at Hewlett-Packard.

Walker holds a bachelor of science degree with joint honors in chemistry and business studies from [Loughborough University](/org/loughborough-university) in England and was awarded an Honorary Doctorate of Business Administration from the [University of Sunderland](/org/university-of-sunderland) in 2018.

She is a board member and CMO Growth Council member of the [Association of National Advertisers](/org/association-of-national-advertisers) (ANA). Walker was recognized by Forbes as one of the Top 15 Most Influential CMOs in the World in 2017 and 2018. She also sponsors multiple initiatives to accelerate female leadership within [Cisco](/org/cisco) and is a strong supporter of the #SeeHer movement, started by the ANA with the goal of accurately portraying women and girls in the media by 2020. Walker also serves on the advisory council for the Salvation Army of Silicon Valley.

Karen Walker

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the [University of Pennsylvania](/org/university-of-pennsylvania). He received his M.D. from the Perelman School of Medicine, [University of Pennsylvania](/org/university-of-pennsylvania), in 2001 and his Ph.D. in Neuroscience from [University of Pennsylvania](/org/university-of-pennsylvania) in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from [Yale University](/org/yale-university) in 1994.

Daniel M. Skovronsky

Steve Fry is senior vice president, human resources and diversity, for Eli Lilly and Company.

Since joining Lilly in 1987 as a scientific systems analyst in Lilly Research Laboratories, Steve has held a range of roles in information technology and human resources. Following a series of managerial assignments, Steve served as human resources director for Lilly’s U.K. affiliate and then as executive director of human resources for the U.S. affiliate. In 2004 he was named managing director of the Australian affiliate, returning to the U.S. in 2007 to provide HR leadership for the global sales and marketing organization before accepting the role of vice president supporting the Lilly Bio-Medicines and Emerging Markets business units. He assumed his current role in 2011.

Steve earned his bachelor’s degree in information systems from the [University of Indianapolis](/org/university-of-indianapolis).

Steve serves on the board of trustees at the [University of Indianapolis](/org/university-of-indianapolis) and the governance board for [Make-A-Wish](/org/make-a-wish) in Ohio, Kentucky, and Indiana.

Stephen F. Fry

Dave Ricks is chairman and chief executive officer of Eli Lilly and Company. He was elected chairman of the company’s board effective June 2017.

A 20-year Lilly veteran, Dave served as president of Lilly Bio-Medicines from 2012 to 2016. Previously, he was president of Lilly USA, the company’s largest affiliate, from 2009 to 2012. He served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. And he was general manager of Lilly Canada from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.

Dave earned a bachelor of science degree from [Purdue University](/org/purdue-university) in 1990 and a master of business administration degree from [Indiana University](/org/indiana-university) in 1996.

Dave is president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). He serves as treasurer on the board of Pharmaceutical Research and Manufacturers of America (PhRMA). Dave is also on the boards of the Central Indiana Corporate Partnership and Adobe, and he chairs the [Riley Children’s Foundation](/org/riley-childrens-foundation) board of governors.

David A. Ricks

Kimberly H. Johnson joined the Board of Directors in February of 2021. Johnson serves as executive vice president and chief operating officer of the Federal National Mortgage Association (“Fannie Mae”) and is a member of [Fannie Mae](/org/fannie-mae)’s management committee. 

Prior to serving as executive vice president and chief operating officer, Johnson held various leadership positions with [Fannie Mae](/org/fannie-mae), including chief risk officer. Before joining [Fannie Mae](/org/fannie-mae) in 2006, Johnson was a director at Credit Suisse Group AG.

Johnson holds a bachelor of arts degree in economics from [Princeton University](/org/princeton) and a master of business administration in finance from Columbia Business School. She is a member of the board of trustees for [Princeton University](/org/princeton) and sits on the board of directors for several nonprofit organizations.



Kimberly H. Johnson

Anat Ashkenazi is senior vice president and chief financial officer for Eli Lilly and Company.

Since joining Lilly in 2001, Anat has held a range of roles across strategy, finance and Six Sigma. Most recently, she served as senior vice president, controller and CFO of Lilly Research Laboratories. In this role, she oversaw the CFOs of the company’s commercial businesses, as well as those for research and development, manufacturing and quality, and G&A functions. She also led the corporate strategic planning team, business transformation office, and served as CFO for several of the company’s global business areas. Prior to joining Lilly, she worked in financial services at Ma’alot Standard & Poor’s and at Ha'poalim Bank in Israel. 

Anat earned a bachelor’s degree from the Hebrew University in finance and economics and a master of business administration from [Tel Aviv University](/org/tel-aviv-university).

Anat Ashkenazi

Edgardo Hernandez is senior vice president at Eli Lilly and Company and president of manufacturing operations.

Ed served as senior vice president of global parenteral drug product, delivery devices and regional manufacturing from 2018 until 2021. In this role, he was responsible for global parenteral manufacturing, emerging markets manufacturing, drug-product contract manufacturing, packaging, and distribution operations. Ed provided oversite for manufacturing sites in 12 countries throughout North America, South America, Europe, and Asia; these sites manufacture the final parenteral product that reaches patients.

Previously, Ed was vice president of Fegersheim Operations for Lilly’s manufacturing site located in France. He joined Lilly in 2005 as an engineering services leader for Lilly del Caribe in Puerto Rico, after working for several years in various positions for [Pfizer](/org/pfizer) and Pharmacia. Before that, he served as site head for two other Lilly manufacturing sites: Indianapolis Active Pharmaceutical Ingredient manufacturing from 2014 until 2016, and PR06 in Puerto Rico from 2012 until 2014.

Ed is a native of Puerto Rico and holds bachelor’s and master’s degrees in chemical engineering from the University of Puerto Rico and [North Carolina State University](/org/north-carolina-state-university), respectively.

Edgardo Hernandez

Patrik Jonsson is a senior vice president of Eli Lilly and Company, and the president of Lilly Bio-Medicines.

Since joining Lilly in 1991 as a sales representative, Patrik has held a number of positions in sales, marketing and general management. He served as European marketing director for Zyprexa and the neuroscience customer group, as managing director of Sweden and later of Scandinavia (Sweden, Norway and Denmark), and as president and general manager of Eli Lilly Italia. In 2012, when Lilly announced a new structure for the company’s European business, Patrik assumed additional responsibilities for the countries in central and southeastern Europe. In 2014, he became president and general manager of Lilly Japan.

Patrik is a business graduate from Lund University, School of Economics and Management, in Sweden.

He is the past chair of the Japan-based executive committee of [PhRMA](/org/phrma), and served on the board of the American Chamber of Commerce in Japan.

Patrik Jonsson

Johna Norton is senior vice president of Global Quality for Eli Lilly and Company.

Johna joined Lilly in 1990 as an analytical chemist. She went on to hold positions with increasing responsibility in quality assurance and quality control, supporting manufacturing and process development at both Lilly facilities and with Lilly’s external manufacturing partners. Throughout her career, she has worked at multiple Lilly manufacturing sites, including sites in Indiana, Ireland and Puerto Rico. Prior to her current role, Johna was vice president, Quality, for Lilly’s Active Pharmaceutical Ingredient (API) manufacturing network, Puerto Rico manufacturing, and Product Research and Development. 

She holds a bachelor’s degree in chemistry from [Gannon University](/org/gannon-university) and a master’s degree in analytical chemistry from [Miami University](/org/miami-university). 

In 2017, FiercePharma named Johna one of the Top Women in Life Sciences.

Johna L. Norton

Anne White is a senior vice president of Eli Lilly and Company and president of Lilly Oncology.

Anne has held a range of roles in drug development across multiple therapeutic areas, including oncology, neuroscience and infectious diseases. She has led the development of multiple late-phase opportunities and has led teams in successfully submitting and achieving new drug approvals for several new medicines. Anne has also had roles leading early phase drug development and patient tailoring in oncology. Her current and past responsibilities include global leadership and direction of several significant change transformations resulting in improved speed, efficiency and increased organizational health.

Most notably, Anne has led Lilly’s effort to speed drug development, from target identification through successful launch. Anne served most recently as vice president of Portfolio Management, Chorus and Next Generation Research and Development, with previous roles of vice president of Oncology Clinical Development and chief operating officer for oncology. She has over 25 years of experience in the pharmaceutical industry.

Anne also has experience in small-company pharma, having founded and led a startup company in oncology drug development, collaborating with the [Moffitt Cancer Center](/org/moffitt-cancer-center) and the [National Cancer Institute](/org/national-cancer-institute). Anne earned a bachelor’s degree in engineering from the University of Michigan.

Anne was awarded the Lilly Women’s Network Award for her efforts in mentoring and supporting women in the workplace. She was named to the first President’s Council in Lilly Research Laboratories in recognition for her leadership and impact on others.

Anne E. White

Leigh Ann Pusey is the senior vice president of Corporate Affairs and Communications for Eli Lilly and Company.

Leigh Ann joined Lilly in June 2017. Prior to joining Lilly, Leigh Ann was president and chief executive officer of the American Insurance Association (AIA) from 2009 to June 2017. Prior to that, she served in several AIA leadership positions, including chief operating officer and senior vice president for government affairs. From 1997 to 2000, she served as that company's senior vice president of public affairs.

From 1995 to 1997, Leigh Ann served as director of communications for the Office of the Speaker of the [U.S. House of Representatives](/org/u-s-house-of-representatives), and from 1993 to 1994, she was the deputy director of communications for the Republican National Committee. From 1990 to 1992, she served as special assistant and then deputy assistant to the president for the White House Office of Public Liaison.

Leigh Ann earned a bachelor’s degree in public administration from [Samford University](/org/samford-university) in 1984.

Leigh Ann served on the board of the Insurance Institute for Highway Safety, was on the board of The George Washington Graduate School of Political Management and was a member of the [U.S. Chamber of Commerce](/org/chamber-of-commerce-of-the-united-states-of-america)’s Committee of 100.

Leigh Ann Pusey

Jamere Jackson, chief financial officer of Hertz Global Holdings Inc., was elected to the Eli Lilly and Company board of directors in 2016.

Prior to joining Hertz Global Holdings Inc., Jackson was chief financial officer of Nielsen Holdings plc. Before joining Nielsen, he spent nearly 10 years at [General Electric](/org/general-electric) in a variety of financial leadership roles in GE Corporate, GE Aviation and GE Oil and Gas. Prior to joining GE, he held several roles in finance, mergers and acquisitions, and strategic planning at [Procter & Gamble](/org/procter-gamble), Yum Brands (Pizza Hut), First Data Corporation and Total System Services.

Jackson received his undergraduate degree in finance and business economics from the [University of Notre Dame](/org/university-of-notre-dame) in 1990 and is a certified public accountant.

Jamere Jackson

Jackson Tai, former vice chairman and chief executive officer, DBS Group Holdings Ltd and [DBS Bank](/org/dbs-bank) Ltd, was elected to the Eli Lilly and Company board of directors in 2013.

In 1999, Tai joined DBS Group and [DBS Bank](/org/dbs-bank) (formerly the Development Bank of Singapore), one of the largest financial services groups in Asia, as chief financial officer. He served DBS as president and chief operating officer from 2001 to 2002, and as vice chairman and chief executive officer from 2002 to 2007.

From 1974 to 1999, Tai was an investment banker with J.P. Morgan & Co. While at J.P. Morgan, Tai established the firm’s Japan capital markets business, based in Tokyo; founded the firm’s global real estate investment banking business, based in New York; served as the firm’s senior officer for Asia Pacific, based in Tokyo; and served as the firm’s senior officer for the Western United States, based in San Francisco.

Tai serves as a non-executive director of Mastercard Incorporated and of HSBC Holdings PLC, where he is chairman of the risk committee. In the nonprofit sector, Tai is a director of the Metropolitan Opera, a trustee of [Rensselaer Polytechnic Institute](/org/rensselaer-polytechnic-institute), and a member of the Harvard Business School Asia-Pacific Advisory Board and the Harvard China Advisory Group.

Tai received a bachelor of science degree from [Rensselaer Polytechnic Institute](/org/rensselaer-polytechnic-institute) in 1972 and a master of business administration degree from [Harvard University](/org/harvard) in 1974.

Jackson Tai

Hakim most previously served as executive vice president, general counsel and secretary at WellCare Health Plans, where she provided strategic counsel on a broad range of legal, business and operational matters for the company and its board of directors. She was recently recognized as General Counsel of the Year in 2019 by Corporate Counsel. Before WellCare, Hakim served as divisional vice president, associate general counsel for intellectual property litigation at Abbott Laboratories, and later as the company's divisional vice president, associate general counsel for litigation. She began her career at Latham Watkins after earning her law degree from [Harvard University](/org/harvard), and also worked for 12 years at Foley & Lardner LLP.

Eli Lilly

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Discover similar companies